Development, Genetics and Recombinant Antibody

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Development

Genetics

Recombinant Antibody

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

NOVEMBER 9, 2023

Novel platforms This session will begin with chariperson’s remarks from Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare, which will be followed by a keynote presentation by Agnieszka Kielczewska, PhD, Director, Research, Antibody Discovery and Screening, Biologics Discovery, Amgen.

Engineer

Engineer Antibody Protein In-Vivo

Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors

The Pharma Data

JANUARY 18, 2021

By selectively targeting the tumor microenvironment, BT-001 is expected to elicit a much stronger and more effective antitumoral response and greatly increase the safety and tolerability profile of the anti-CTLA4 antibody. BT-001 is being co-developed through a 50/50 collaboration between Transgene and BioInvent. 19, 2021 06:30 UTC.

Trials

Trials Antibody Engineer Clinical Trials

Clinical Research Informer

What to expect from PEGS Europe 2023: Day 2

Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors

Stay Connected